Non-Hodgkin's Lymphoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

NON-HODGKIN’S LYMPHOMA A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCE...

Author: Health Publica Icon Health Publications

13 downloads 889 Views 5MB Size Report

This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form

DOWNLOAD PDF

NON-HODGKIN’S LYMPHOMA A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES

J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS

ii

ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1

Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Non-Hodgkin’s Lymphoma: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83661-2 1. Non-Hodgkin’s Lymphoma-Popular works. I. Title.

iii

Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.

Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail: [email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.

v

Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on non-Hodgkin’s lymphoma. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.

vi

About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.

vii

About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health

ix

Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON NON-HODGKIN’S LYMPHOMA ................................................................ 3 Overview........................................................................................................................................ 3 Federally Funded Research on Non-Hodgkin’s Lymphoma........................................................... 3 E-Journals: PubMed Central ....................................................................................................... 10 The National Library of Medicine: PubMed ................................................................................ 11 CHAPTER 2. NUTRITION AND NON-HODGKIN’S LYMPHOMA..................................................... 109 Overview.................................................................................................................................... 109 Finding Nutrition Studies on Non-Hodgkin’s Lymphoma ....................................................... 109 Federal Resources on Nutrition ................................................................................................. 122 Additional Web Resources ......................................................................................................... 123 CHAPTER 3. ALTERNATIVE MEDICINE AND NON-HODGKIN’S LYMPHOMA .............................. 125 Overview.................................................................................................................................... 125 National Center for Complementary and Alternative Medicine................................................ 125 Additional Web Resources ......................................................................................................... 139 General References ..................................................................................................................... 139 CHAPTER 4. DISSERTATIONS ON NON-HODGKIN’S LYMPHOMA ................................................ 141 Overview.................................................................................................................................... 141 Dissertations on Non-Hodgkin’s Lymphoma ............................................................................ 141 Keeping Current ........................................................................................................................ 142 CHAPTER 5. CLINICAL TRIALS AND NON-HODGKIN’S LYMPHOMA ........................................... 143 Overview.................................................................................................................................... 143 Recent Trials on Non-Hodgkin’s Lymphoma ............................................................................ 143 Keeping Current on Clinical Trials ........................................................................................... 163 CHAPTER 6. BOOKS ON NON-HODGKIN’S LYMPHOMA ............................................................... 165 Overview.................................................................................................................................... 165 Book Summaries: Online Booksellers......................................................................................... 165 The National Library of Medicine Book Index ........................................................................... 167 Chapters on Non-Hodgkin’s Lymphoma ................................................................................... 168 CHAPTER 7. MULTIMEDIA ON NON-HODGKIN’S LYMPHOMA .................................................... 169 Overview.................................................................................................................................... 169 Bibliography: Multimedia on Non-Hodgkin’s Lymphoma ........................................................ 169 CHAPTER 8. PERIODICALS AND NEWS ON NON-HODGKIN’S LYMPHOMA ................................. 171 Overview.................................................................................................................................... 171 News Services and Press Releases.............................................................................................. 171 Academic Periodicals covering Non-Hodgkin’s Lymphoma ...................................................... 174 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 177 Overview.................................................................................................................................... 177 NIH Guidelines.......................................................................................................................... 177 NIH Databases........................................................................................................................... 179 Other Commercial Databases..................................................................................................... 181 APPENDIX B. PATIENT RESOURCES ............................................................................................... 183 Overview.................................................................................................................................... 183 Patient Guideline Sources.......................................................................................................... 183 Associations and Non-Hodgkin’s Lymphoma............................................................................ 190 Finding Associations.................................................................................................................. 191 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 193 Overview.................................................................................................................................... 193 Preparation................................................................................................................................. 193 Finding a Local Medical Library................................................................................................ 193 Medical Libraries in the U.S. and Canada ................................................................................. 193

x

Contents

ONLINE GLOSSARIES................................................................................................................ 199 Online Dictionary Directories ................................................................................................... 201 NON-HODGKIN’S LYMPHOMA DICTIONARY ................................................................. 203 INDEX .............................................................................................................................................. 269

1

FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with non-Hodgkin’s lymphoma is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about non-Hodgkin’s lymphoma, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to non-Hodgkin’s lymphoma, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on non-Hodgkin’s lymphoma. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to non-Hodgkin’s lymphoma, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on non-Hodgkin’s lymphoma. The Editors

1

From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.

3

CHAPTER 1. STUDIES ON NON-HODGKIN’S LYMPHOMA Overview In this chapter, we will show you how to locate peer-reviewed references and studies on non-Hodgkin’s lymphoma.

Federally Funded Research on Non-Hodgkin’s Lymphoma The U.S. Government supports a variety of research studies relating to non-Hodgkin’s lymphoma. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to non-Hodgkin’s lymphoma. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore non-Hodgkin’s lymphoma. The following is typical of the type of information found when searching the CRISP database for non-Hodgkin’s lymphoma: •

Project Title: EPIDEMIOLOGY OF NON HODGKINS'S LYMPHOMA DATA ANALYSIS Principal Investigator & Institution: Holly, Elizabeth A.; Professor; Epidemiology and Biostatistics; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001; Project Start 03-JAN-2001; Project End 31-DEC-2002

2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).

4

Non-Hodgkin’s Lymphoma

Summary: A population-based case-control study of non-Hodgkin's lymphoma (NHL) that included nearly 1600 patients with NHL and more than 2500 control participants was conducted by the Principal Investigator and colleagues in the San Francisco Bay Area between 1988 and 1995. NHL cases were obtained using rapid case ascertainment by the Northern California Cancer Center and control participants were identified using random digit dial and the Healthcare Financing Administration files. Pathology materials for the NHL patients included in the study were reviewed and classified of this study are: 1) to evaluate the association between exposure data collected in this large study and subtypes of NHL defined using the Working Formulation with emphasis on the investigation of risk factors found to be of importance in the main analyses of all NHL; and 2) to complete detailed analyses to investigate the association between risk for NHL and occupational and chemical exposures including Agent Orange, reproductive and hormonal exposures among women , support for hypotheses that indicated there are etiologic differences across NHL subtypes that can be characterized by a unique set of associated risk factors. Differentiation of risk factors by NHL subtypes will provide important clues to detailed analyses between exposures of interest and risk for NHL with adjustment for potential confounders and effect modifiers. These data may explain inconsistencies in results from earlier NHL studies constrained by limited sample size and exposure data. They also may provide important additional information about the role of exposures that alter Th1 or Th2 pathways and the process of lymphomagenesis. These data will be used as preliminary results for a larger Bay Area study of lymphoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: GENES INVOLVED IN AIDS LYMPHOMAGENESIS Principal Investigator & Institution: Teitell, Michael A.; Assistant Professor Iv; Pathology; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2001; Project Start 30-SEP-1998; Project End 29-SEP-2003 Summary: (Applicant's Description): The current proposal encompasses 5 years and focuses on identifying new genes, or altered levels of expression of known genes, and possible mechanism(s) of lynphomagenesis in individuals with AIDS. Approximately 5 to 10% of AIDS patients develop non-Hodgkin's lymphoma (NHL), a large number of which are classified by multiple criteria as high grade B-cell immunoblastic lymphoma (BIBL). This investigation utilizes guidance provided by three established researchers, each of whom provides a unique expertise and set of reagents. Early stages utilize Suppression Subtractive Hybridization (SSH) and DNA macro- and microarray gene fragment screening of a BIBL subset of 15 genetically defined AIDS-NHL tissue samples. This BIBL subset lacks EBV and K S HV/HHV-8 infections and also lacks generic lesions or dysregulated expression of any of the proto-oncogenes or tumor suppressor genes frequently found in AIDS-NHL. Dr. C. Denny, whose laboratory routinely employs Representational Difference Analysis (RDA), will guide SSH cDNA-isolation from the BIBL subset and Dr. S. Nelson will provide support for DNA microarray screening technology should it become necessary. Gene products differentially expressed in AIDSBIBL versus hyperplastic lymph node material will be isolated and used to establish an index set of gene fragments against which other lymphoma and non-lymphomatous samples will be compared. Commonly dysregulated genes will be evaluated by multiple criteria and selected candidates will be checked for cytokine inducibility, cloned, sequenced, and analyzed for relatedness to known sequences. Once obtained, novel and known candidate cDNAs will be moved into CMV-based and inducible expression

Studies

5

vector systems containing FLAG epitope tags under the guidance of Dr. R. Wall. These t a g ged cDNA candidate clones will be stably transformed into three immortalized premalignant murine B-cell lines, established previously in the laboratory of Dr. J. Braun. Transformants created with novel cDNAs will be assayed for resistance to NK cytolysis and MHC class I expression, while previously defined cDNAs will be similarly assayed and studied further based o n a v ailable reagents and current knowledge of their function(s). Transformants exhibiting NK cell resistance and elevated MHC class I expression will be evaluated for in vivo tumor formation in Balb/c-scid and syngeneic (BWF1 or AJ9) mice. Tumorigenicity in immune competent and deficient hosts will be assessed by BIBL-FLAG immunohistochemistry, routine h i stology, mortality curves, and organ morphology/weights. Genes with significant involvement in the etiology and/or progression of lymphomagenesis, or those with reproducible in vitro biochemical effects, will be further characterized by molecular methods. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: LYMPHOMA

HIV

INFECTED

ENDOTHELIUM

AND

NONHODGKINS

Principal Investigator & Institution: Moses, Ashlee V.; Assistant Professor; Molecular Microbiol and Immun; Oregon Health & Science University Portland, OR 972393098 Timing: Fiscal Year 2001; Project Start 20-SEP-1998; Project End 31-AUG-2003 Summary: (Adapted from the applicant's description) AIDS patients have an unusually high incidence of aggressive B cell non-Hodgkin's lymphomas (AIDS-NHL) that frequently involve extranodal sites, in particular the gut, liver brain and bone marrow. While neoplastic B cells are not directly infected with human immunodeficiency virus type 1 (HIV), interaction with HIV-infected non-B accessory cells at extranodal sites may contribute to localization and development of malignant clones. This group have previously shown that bone marrow microvascular endothelial cells (MVEC) are a natural target for HIV in vivo and in vitro. Since MVEC interact with B cells during hematopoiesis as well as during leucocyte trafficking and extravasation, they hypothesize that HIV infection of MVEC may influence neoplastic B cell attachment and growth and facilitate extranodal lymphoma development: Using a novel MVECenriched stromal culture system, they have shown that HIV infection of stromal cultures from seronegative lymphoma patients induces the sustained outgrowth of EBV-negative B lymphoma cells which are dependent on stroma for growth. They have also demonstrated that the only cellular component infected by HIV in these cultures are MVEC, and that purified populations of infected but not uninfected brain MVEC are equally supportive of neoplastic B cell growth. These data suggest that HIV infection of permissive MVEC alters their ability to induce and sustain malignant B cell growth. The investigators have recently identified a mechanism whereby HIV regulates MVEC-B lymphoma interactions. Specifically, CD40 expression is preferentially induced on infected MVEC allowing CD40-mediated upregulation of VCAM-1 and subsequent VCAM-1/VLA-4 mediated MVEC-B cell binding. This project will extend these results by characterizing the relative kinetics of CD40 expression and CD40-mediated VCAM-1 expression in HIV-infected MVEC. They will also identify the viral gene(s) which mediate these events using HIV deletion mutants and recombinant viral constructs containing individual viral genes. Finally, this group will characterize the signal transduction pathways through which HIV regulates CD40 expression and CD40mediated VCAM-1 expression using a transcriptional readout system, biochemical assays for phosphorylation of signal transduction intermediates and transdominant

6


negative mutants which block signal transduction. Identification of these mechanisms may suggest therapeutic targets to prevent development of extranodal B cell neoplasms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: IMMUNOLOGIC STRATEGIES FOR THE TREATMENT OF ACUTE LEUKEMIA Principal Investigator & Institution: Ritz, Jerome; Professor of Medicine; Dana-Farber Cancer Institute 44 Binney St Boston, MA 02115 Timing: Fiscal Year 2001 Summary: With the advent of intensive combination chemotherapy programs, the great majority of patients with newly diagnosed hematologic malignancies can be induced into a complete remission status. However, despite initial sensitivity, resistance to chemotherapy with subsequent relapse is the primary cause of treatment failure in these diseases. New strategies to prevent relapse are clearly needed. In previous studies, we have examined immunologic approaches to induce or enhance anti-tumor immunity and have focused on immune modulation with exogenous lymphokines such as IL-2. In patients with solid tumors we demonstrated that relatively low doses of IL- 2 could be safely administered for prolonged periods resulting in the marked increase in the total number of circulating natural killer (NK) cells and NK activity. Similar results have also been found in patients with hematologic malignancies after either autologous or T cell depleted allogeneic BMT. In patients with AML, the use of IL-2 following completion of post-remission intensification appears able to enhance non-specific cytotoxicity against autologous AML cells without excessive systemic toxicity and thus far few relapses have been observed following immunotherapy. Studies proposed ina the next funding period will further extend our examination of the role of il-2 to enhance anti-tumor immunity. We will also begin to examine new approaches to enhance tumor immunity in patients with leukemia or lymphoma using strategies developed in other projects within this program. The Specific Aims of this project are listed below; 1. To evaluate the systemic administration of cytokines to enhance both specific and nonspecific immunity against autologous leukemia and lymphoma. 1.1 To determine the immunologic effects of prolonged low dose IL-2 infusion and bolus IL-2 infusion when administered to patients with AML in first CR. 1.2 To define the immunologic effects of IL-2 administration following autologous BMT for B cell non-Hodgkin's lymphoma. 1.3 To evaluate the potential use of other cytokines for enhancement of non-specific immunity in vivo in patients with AML and B cell non-Hodgkin's lymphoma. 1.4 To examine the efficacy of humanized anti-CD33 monoclonal antibody in conjunction with IL-2 in patients with relapsed AML. 2. To evaluate new methods for inducing or enhancing autologous antitumor immunity in vivo based on the ability to enhance tumor cell expression of costimulatory molecules in vitro. 3. To develop methods for in vitro activation and expansion of autologous leukemia or lymphoma reactive T cells for use in adoptive cellular therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: NOVEL RADIOIMMUNOTHERAPY FOR LYMPHOMA Principal Investigator & Institution: Butrynski, James E.; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, WA 98109 Timing: Fiscal Year 2001; Project Start 18-AUG-2000; Project End 11-MAR-2002 Summary: The candidate's immediate goal is to acquire critical scientific and clinical training to enable him to pursue independent investigation with a long-term goal of

Studies

7

developing innovative therapies for non-Hodgkin's lymphoma (NHL). Incidence of NHL is increasing and improvements in therapy are needed. Radiolabeled antibody therapy has proven effective in treating NHL, but is limited by delivery of radiation to normal tissues due to circulating non-tumor bound radiolabeled antibody. The proposed program will integrate two complimentary approaches 1. preclinical development of a novel radioimmunotherapeutic approach and 2. clinical evaluation of radiolabeled antibody therapy. In preclinical studies, we hypothesize that rapidly removing circulating non-tumor bound radioisotope will decrease radiation delivered to normal tissues and improve relative radiation delivery to tumor. Specifically, our strategy involves exogenous administration of an enzyme, beta-lactamase, in order to cleave a circulating cephalosporin-based radioimmunoconjugate (RIC), resulting in rapid cleavage and removal of radioisotope from the body by the kidney. We further hypothesize the effectiveness of this approach will depend on stable intracellular retention of radioisotope in tumor and on more rapid tumor targeting. Biodistribution studies in murine and nonhuman primate models will b e performed with cleavable RICs that are internalized and retained by the tumor cell to ascertain if our approach will result in improvement in the delivery of radiation to tumor compared to normal tissues. In clinical studies, the candidate will assess the risk of secondary malignancies associated with myeloablative Iodine-131 anti-CD20 antibody and autologous stem cell transplant in patients with lymphoma previously treated and in ongoing trials. Furthermore, a proposed dose escalation trial in later years of this grant is anticipated with the optimized cleavable RICs developed in the preclinical proposal. In addition to these preclinical and clinical investigations, a rigorous didactic and mentoring program in clinical trial design will provide the candidate the foundation to implement and supervise clinical trials of novel therapies for NHL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: ROLE OF HUMAN GAMMA DELTA T CELLS IN TUMOR IMMUNITY Principal Investigator & Institution: Bukowski, Jack F.; Brigham and Women's Hospital 75 Francis Street Boston, MA 02115 Timing: Fiscal Year 2001; Project Start 03-JUL-2001; Project End 30-JUN-2004 Summary: (provided by applicant): There is increasing evidence to suggest that gammadelta T cells play an important role in defense against a variety of malignancies in humans. Human gamma-delta T cells expand in vivo, and can become up to 42% of all peripheral blood T cells during non-Hodgkin's lymphoma. This gamma-delta T cell expansion can be recapitulated in vitro by culturing peripheral blood mononuclear cells (PBMC) with lymphoma or myeloma cell lines, and the expanded gamma-delta T cells from such cultures can kill a wide variety of lymphoid myeloid, and epithelial tumor cells. Reconstitution of severe combined immunodeficiency (SCID) mice with human gamma/delta T cells prolongs survival from lymphoma. However, the basis of tumor cell recognition by human gamma-delta T cells is poorly understood, and very little data exists regarding the in vivo regulation of human gamma-delta T cells. This lack of knowledge of human gamma-delta T cell cancer biology is critically important, since information from mouse gamma-deltaT cell studies cannot be readily extrapolated to humans, since non-peptide alkylamine and organophosphate antigens recognized by the dominant population of human peripheral blood gamma-delta T cells, Vgamma2Vdelta T cells, are completely different from the protein antigens recognized by mouse gamma-delta T cells. This crucial difference between mouse and human gamma-delta T cells compels us to examine directly in an in vivo model of human

8


neoplasia the behavior of human gamma T cells, and to explore receptor-ligand interactions between Vgamma2Vdelta T cells and lymphoid, myeloid, or epithelial tumor cells. We will identify which of these receptor-ligand interactions is important in human gamma-delta T cell-mediated antineoplastic activity in an in vivo SCID mouse model. We will attempt to activate, with specific antigens, human VgammaVdelta2 T cells transplanted into SCID mice to test the hypothesis that such activation will boost gamma-delta T cell-mediated antineoplastic effects. Finally, we will attempt to modulate gamma-delta T cell function in healthy humans by ingestion of antigens recognized by gamma/delta T cells. These studies will thus help define the role of VgammaVdelta2 T cells in human tumor immunity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: SIGNAL TRANSDUCTION IN LYMPHOMA Principal Investigator & Institution: Carpenter, Christopher L.; Assistant Professor; Beth Israel Deaconess Medical Center St 1005 Boston, MA 02215 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: Anaplastic large cell lymphoma (ALCL) constitutes about 8 percent of nonHodgkin's lymphomas in the general population and 25 percent in patients with human immunodeficiency virus (HIV) infection. All ALCL express the tumor necrosis factor (TNF) receptor family member CD30. More than 60 percent of the cases of ALCL in the non-HIV population are caused by activation of the protein tyrosine kinase anaplastic lymphoma kinase (ALK). ALK is usually activated by a 2:5 chromosomal translocation that produces a fusion with nucleophosmin (NPM), called NPM-ALK. Very little is known about the signal transduction pathways activated by NPM-ALK and thus, how it causes lymphoma. ALCL is unique because CD30 stimulation arrests cell growth. Although antibodies to CD30 are being used as therapy, the mechanism by which they arrest cell growth is not known. Our goals are to develop a foundation of knowledge about the signaling pathways necessary for NPM-ALK to cause lymphoma and to delineate the pathway by with CD30 stimulation arrests growth in ALCL. Phosphoinositide 3-kinase (PI3K), signal transducer and activator of transcription (STAT) 5 and phospholipase C gamma, are activated by NPM-ALK. Our studies suggest NPM-ALK phosphorylates the scaffolding proteins Gab2 and IRS-1 and thereby activates PI 3-kinase and probably STAT 3 and 5. We will determine the pathways by which NPM-ALK activates PI3K and STAT proteins and the importance of these pathways for lymphomagenesis. We will use both biochemical and genetic approaches to answer these questions. Our studies indicate that CD30 causes growth arrest as a result of inhibition of PI3K and induction of the cyclin- dependent kinase inhibitor, p21waf1. Using primarily a biochemical approach, we will establish the signaling pathway by which CD30 activation arrests cell growth in ALCL. The results of these studies should provide critical insights into how ALCL develops and how CD30 stimulation works as therapy. This knowledge may also help in developing treatment for other CD30 positive lymphomas and understanding how other oncogenes cause cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

•

Project Title: SYNERGISTIC LYMPHOMAS

CHEMO

RADIOIMMUNOTHERAPY

FOR

B

Principal Investigator & Institution: Johnson, Timothy A.; Medicine; University of Washington Seattle, WA 98195

Studies

9

Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: The long-term objectives of this proposal are 1) to improve therapy for nonHodgkin's lymphoma using combinations of radioimmunotherapy and chemotherapy and 2) to discern the intracellular mechanisms responsible for the synergistic cytotoxicity mediated by these two therapeutic modalities. Preliminary data demonstrate marked synergism in vitro between Iodine-131-radiolabeled anti-CD20 antibody and nucleoside analogs; moderate synergism with topoisomerase inhibitors; and non synergism with cisplatin or 4-hydroxycyclophosphamide. The specific aims of this proposal are four-fold. First, we will test the hypothesis that nucleoside analogs are a more potent class of radiosensitizing drugs for use with I-131-anti-CD20 antibodies than other drug classes using human-derived lymphoma cell lines in vitro. Conclusions will be confirmed in three different in vitro cytotoxic assays, including a clonogenic outgrowth assay, and data will be analyzed by a rigorous isobolographic methodology. Second, we will investigate the mechanisms involved in the potent synergism observed with the nucleoside analogs by assaying well-established effects of the analogs, including the induction of apoptosis, the enhancement of radiation- induced DNA damage, and the incorporation of nucleoside analog into repair DNA. Third, we will investigate the role of Fs-dependent apoptosis in the synergism between anti-CD20 radioimmunotherapy and nucleoside analogs. Fas-dependent and Fas-independent signaling will be studied in experiments employing specific anti-Fas receptor and antiFas ligand blocking antibodies, soluble protein inhibitors of the caspase proteins, and immunoblotting of activated forms of caspase 3 (CPP32), caspase 8 (FLICE), and poly(ADP-ribose) polymerase. Fourth, the most promising combinations of radiolabeled anti-CD20 antibody and chemotherapy will be tested for efficacy in two mouse tumor xenograft models, including a subcutaneous tumor model in nude mice and a disseminated tumor model in SCID mice. The proposed studies will be performed in the laboratory of Dr. Oliver Press at the University of Washington. The large patient base and intense focus on the treatment of lymphomas and other hematologic malignancies at both the University of Washington and the Fred Hutchinson Cancer Research Center and the expertise of the radioimmunotherapy group at these institutions will facilitate rapid translation of promising combinations of radioimmunotherapy and chemotherapy into clinical trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •

Project Title: TREATMENT AND OUTCOME OF AIDS-RELATED LYMPHOMA Principal Investigator & Institution: Diamond, Catherine A.; Medicine; University of California Irvine Campus Dr Irvine, CA 92697 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2007 Summary: Non-Hodgkin's lymphoma (NHL) is an increasing cause of death among people with acquired immunodeficiency (AIDS) due to declining rates of opportunistic infection (OI) with the use of highly active antiretroviral therapy (HAART). While the prognosis of AIDS- related NHL has been poor in the past, HAART may improve outcomes. Specific Aims: 1) We will identify NHL patients with and without AIDS from the population-based cancer registry using a rapid case ascertainment method. 2) We will describe HIV-specific patient and treatment characteristics of AIDS-NHL patients and distinguish which factors influence prognosis. 3) We will describe tumor characteristics and cancer treatment in NHL patients with and without AIDS and distinguish which oncologic features influence prognosis. 4) We will determine how the use of HAART influences the International Prognostic Index (IPI) and form an original prognostic model. Research Design: Using rapid case ascertainment, we will contact all

10 Non-Hodgkin’s Lymphoma

AIDS-NHL cases reported in a two-year period to the cancer registry for Orange, San Diego, and Imperial Counties and a sample of non- AIDS NHL cases matched on age, sex and race/ethnicity reported during the same two-year period. We will perform interviews and chart reviews on NHL patients to collect information on biologic factors that influence prognosis such as such as NHL site, stage, and pathologic grade as well as patient-specific features such as race/ethnicity, performance status, and health care access. We will gather data on HIV-specific features including CD4 cell count, HIV viral load, HIV risk factors, and use of HAART for NHL patients with AIDS. We will compare survival, development of co-morbidities/OI, and quality of life (QOL) between NHL patients with and without AIDS over a three-year follow-up period between AIDS patients who receive HAART and those who do not. Lastly, we will determine how the use of HAART influences the IPI and develop a prognostic model that incorporates HIV-related factors, tumor characteristics, HAART, and chemotherapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen

E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “non-Hodgkin’s lymphoma” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for non-Hodgkin’s lymphoma in the PubMed Central database: •

Antibody responses of splenectomized patients with non-Hodgkin's lymphoma to immunization with polyvalent pneumococcal vaccines.. by Petrasch S, Kuhnemund O, Reinacher A, Uppenkamp M, Reinert R, Schmiegel W, Lutticken R, Brittinger G. 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=170631

•

Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. by Ledergerber B, Telenti A, Egger M. 1999 Jul 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28149

•

Sunlight exposure and non-Hodgkin's lymphoma. by Weir E. 2001 Aug 7; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=81350

3 4

Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.

With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.

Studies 11

The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with non-Hodgkin’s lymphoma, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “nonHodgkin’s lymphoma” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for non-Hodgkin’s lymphoma (hyperlinks lead to article summaries): •

A case of non-Hodgkin's lymphoma infiltrating the brachial plexus detected by Ga-67 scintigraphy. Author(s): Ohta H. Source: Ann Nucl Med. 2002 June; 16(4): 297-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12126101&dopt=Abstract

•

A case of primary non-Hodgkin's lymphoma of the transverse colon presenting as inflammatory bowel disease. Author(s): Ramasamy KA, Vignaraja R, Hastings AG, Bessell EM, Snape J. Source: European Journal of Gastroenterology & Hepatology. 2002 December; 14(12): 1401-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12468966&dopt=Abstract

•

A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma. Author(s): Jang GD, Kim SW, Suh CW, Kim EK, Bahng HS, Jeong YH, Park IG, Kim WK, Kim SH, Suh EJ, Park CJ, Ji HS, Lee JS. Source: Journal of Korean Medical Science. 2002 August; 17(4): 555-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12172056&dopt=Abstract

PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.

6


•

A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma. Author(s): Angrilli F, Pennese E, Di Marzio A, Liberatore E, Di Lorenzo R, Fioritoni G. Source: Haematologica. 2002 November; 87(11): 1227-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12414356&dopt=Abstract

•

A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Author(s): Takeyama K, Ogura M, Morishima Y, Kasai M, Kiyama Y, Ohnishi K, Mitsuya H, Kawano F, Masaki Y, Sasaki T, Chou T, Yokozawa T, Tobinai K; Lenograstim/Lymphoma Study Group. Source: Japanese Journal of Clinical Oncology. 2003 February; 33(2): 78-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12629058&dopt=Abstract

•

A literature review of single agent treatment of multiply relapsed aggressive nonHodgkin's lymphoma. Author(s): Webb MS, Saltman DL, Connors JM, Goldie JH. Source: Leukemia & Lymphoma. 2002 May; 43(5): 975-82. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12148908&dopt=Abstract

•

A new weapon in the treatment of non-Hodgkin's lymphoma. Author(s): Lipcamon JD, Sahl B. Source: Radiol Manage. 2002 September-October; 24(5): 13-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12422657&dopt=Abstract

•

A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy. Author(s): Hough RE, Lorigan PC, Poynton C, Newland A, Gupta RK, Foran J, Hancock BW. Source: International Journal of Oncology. 2003 February; 22(2): 421-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12527943&dopt=Abstract

•

A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). Author(s): Joyce RM, Regan M, Ottaway J, Umiel T, Tetreault JC, Levine J, McDermott D, Hurley D, Giallombardo N, Smith T, Lamontagne D, Uhl L, Avigan D. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003; 14 Suppl 1: I21-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12736227&dopt=Abstract

Studies 13

•

A primary non-Hodgkin's lymphoma of bone in Tunisia. A retrospective study of 15 cases. Author(s): Meddeb N, Rammeh N, Elleuch M, Chatti S, Gammoudi A, Sellami S, Boussen H, Baklouti S, Zlitni M. Source: Joint, Bone, Spine : Revue Du Rhumatisme. 2002 December; 69(6): 623-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12537275&dopt=Abstract

•

A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. Author(s): Bessell EM, Burton A, Haynes AP, Glaholm J, Child JA, Cullen MH, Davies JM, Smith GM, Ellis IO, Jack A, Jones EL; Central Lymphoma Group UK. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 February; 14(2): 258-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12562653&dopt=Abstract

•

Abdominal irradiation after chemotherapy in non-Hodgkin's lymphoma: review of 32 patients. Author(s): Brihi E, Akoum R, Saade M, Chahine G. Source: Molecular Immunology. 2003 July; 39(17-18): 1121-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12835089&dopt=Abstract

•

ACOD, a modified CHOP regimen for elderly patients with aggressive nonHodgkin's lymphoma. Author(s): Santoro P, Martinelli G, Ferrucci PF, Mingrone W, Cocorocchio E, Conconi A, Peccatori FA, De Luzio K, Mazzetta C, Zucca E, Cavalli F. Source: Leukemia & Lymphoma. 2003 May; 44(5): 801-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802917&dopt=Abstract

•

Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma. Author(s): Armitage JO, Coiffier B. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2000 March; 11(3): 359-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10811506&dopt=Abstract

•

Acute myeloblastic leukemia in a patient with non-Hodgkin's lymphoma early after double peripheral blood stem-cell transplantation. Author(s): Hashino S, Toyoshima N, Chiba K, Suzuki S, Kurosawa M, Musashi M, Asaka M. Source: Transplantation. 2003 July 15; 76(1): 264-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12865823&dopt=Abstract


•

Acute onset of non-Hodgkin's lymphoma with bowel perforation in a patient with over 15 years' HIV positivity. A case report. Author(s): Greco L, Maggi P, Ialongo P, Lospalluti M, Polizzi RA, Catalano G. Source: Chir Ital. 2002 November-December; 54(6): 893-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12613342&dopt=Abstract

•

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. Author(s): Postema EJ, Oyen WJ, Boerman OC, Corstens FH. Source: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 2003 May; 44(5): 853. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12732690&dopt=Abstract

•

Advances in the management of patients with non-Hodgkin's lymphoma. Author(s): Lionberger JM, Armitage JO. Source: Expert Rev Anticancer Ther. 2001 June; 1(1): 43-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12113132&dopt=Abstract

•

Advances in the treatment of non-Hodgkin's lymphoma. Author(s): Cerny T, Gillessen S. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002; 13 Suppl 4: 211-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12401693&dopt=Abstract

•

Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry. Author(s): Maartense E, Le Cessie S, Kluin-Nelemans HC, Kluin PM, Snijder S, Wijermans PW, Noordijk EM. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 August; 13(8): 1275-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12181252&dopt=Abstract

•

Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: treatment, outcome, and prognostic factors. Author(s): Alici S, Bavbek SE, Kaytan E, Basaran M, Eralp Y, Onat H. Source: American Journal of Clinical Oncology : the Official Publication of the American Radium Society. 2002 October; 25(5): 502-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12393993&dopt=Abstract

Studies 15

•

Alcohol consumption, family history of hematolymphoproliferative cancer, and the risk of non-Hodgkin's lymphoma in men. Author(s): Chiu BC, Weisenburger DD, Cantor KP, Zahm SH, Holmes F, Burmeister LF, Blair A. Source: Annals of Epidemiology. 2002 July; 12(5): 309-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12062917&dopt=Abstract

•

Allogeneic haemopoietic stem cell transplantation for non-Hodgkin's lymphoma. Author(s): Toze CL, Barnett MJ. Source: Best Practice & Research. Clinical Haematology. 2002 September; 15(3): 481-504. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12468401&dopt=Abstract

•

Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Author(s): Verdonck LF. Source: Leukemia & Lymphoma. 1999 June; 34(1-2): 129-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10350340&dopt=Abstract

•

Altered release of tumor necrosis factor and its soluble receptor in non-Hodgkin's lymphoma patients. Author(s): Rathore VB, Advani SH, Nadkarni JJ. Source: Cancer Detection and Prevention. 1999; 23(3): 226-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10337001&dopt=Abstract

•

Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell nonHodgkin's lymphoma. Author(s): Butler MP, Iida S, Capello D, Rossi D, Rao PH, Nallasivam P, Louie DC, Chaganti S, Au T, Gascoyne RD, Gaidano G, Chaganti RS, Dalla-Favera R. Source: Cancer Research. 2002 July 15; 62(14): 4089-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12124346&dopt=Abstract

•

An unusual case of chylothorax complicating non-Hodgkin's lymphoma. Author(s): Larsen S, Manoharan A, Fermanis G, Schonell M. Source: Leukemia & Lymphoma. 2000 June; 38(1-2): 207-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10811466&dopt=Abstract

•

Analysis of internal deletions within the BCL6 gene in B-cell non-Hodgkin's lymphoma. Author(s): Nakamura Y, Saito K, Furusawa S. Source: British Journal of Haematology. 1999 April; 105(1): 274-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10233393&dopt=Abstract


•

Ankylosing spondylitis associated with non-Hodgkin's lymphoma. Author(s): Pavithran K, Raji NL, Thomas M. Source: J Assoc Physicians India. 2002 June; 50: 836-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12240857&dopt=Abstract

•

Antibody-based therapy of non-Hodgkin's lymphoma. Author(s): Foran JM. Source: Best Practice & Research. Clinical Haematology. 2002 September; 15(3): 449-65. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12468399&dopt=Abstract

•

Are blood donors an adequate control group to ascertain HCV prevalence in nonHodgkin's lymphoma patients. Author(s): Iannitto E, De Cantis S, Cirrincione S, Ammatuna E, Di Trapani R, Quintini G, Carroccio A, Mariani G. Source: Journal of Gastroenterology and Hepatology. 2002 September; 17(9): 1039-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12167130&dopt=Abstract

•

Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Author(s): Vallisa D, Berte R, Rocca A, Civardi G, Giangregorio F, Ferrari B, Sbolli G, Cavanna L. Source: The American Journal of Medicine. 1999 May; 106(5): 556-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10335728&dopt=Abstract

•

Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Author(s): Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. Source: British Journal of Haematology. 2002 August; 118(2): 477-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12139735&dopt=Abstract

•

Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma. Author(s): Hamada M, Yakushijin Y, Ohtsuka M, Kakimoto M, Yasukawa M, Fujita S. Source: British Journal of Haematology. 2003 May; 121(3): 439-47. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12716366&dopt=Abstract

•

Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission. Author(s): De Rosa L, Lalle M, Pandolfi A, Ruscio C, Amodeo R. Source: Annals of Hematology. 2002 October; 81(10): 575-81. Epub 2002 September 24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12424539&dopt=Abstract

Studies 17

•

Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-up. Author(s): Bolwell B, Kalaycio M, Sobecks R, Andresen S, Mcbee M, Kuczkowski L, Rybicki L, Pohlman B. Source: Bone Marrow Transplantation. 2002 April; 29(8): 673-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12180112&dopt=Abstract

•

Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin's lymphoma. Author(s): Tomblyn M, Winter JN. Source: Expert Rev Anticancer Ther. 2003 June; 3(3): 281-94. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12820773&dopt=Abstract

•

Autologous or allogeneic hematopoietic cell transplantation for non-Hodgkin's lymphoma? Author(s): Blume KG. Source: Annals of Hematology. 2002; 81 Suppl 2: S9-11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12611059&dopt=Abstract

•

Autologous stem cell transplantation in treatment of aggressive non-Hodgkin's lymphoma. Author(s): Kluin-Nelemans HC. Source: Croatian Medical Journal. 2002 October; 43(5): 561-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12402396&dopt=Abstract

•

Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity. Author(s): Fisher RI. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2002 November 15; 20(22): 4411-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12431961&dopt=Abstract

•

B cell non-Hodgkin's lymphoma in a girl with the DiGeorge anomaly. Author(s): Ramos JT, Lopez-Laso E, Ruiz-Contreras J, Giancaspro E, Madero S. Source: Archives of Disease in Childhood. 1999 November; 81(5): 444-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10519724&dopt=Abstract


•

B-cell stimulation and prolonged immune deficiency are risk factors for nonHodgkin's lymphoma in people with AIDS. Author(s): Grulich AE, Wan X, Law MG, Milliken ST, Lewis CR, Garsia RJ, Gold J, Finlayson RJ, Cooper DA, Kaldor JM. Source: Aids (London, England). 2000 January 28; 14(2): 133-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10708283&dopt=Abstract

•

Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma. Author(s): Berinstein NL, Buckstein R, Imrie K, Spaner D, Mangel J, Tompkins K, Pennell N, Reis M, Pavlin P, Lima A, Couvadia A, Robinson J, Richardson P. Source: Bone Marrow Transplantation. 2002 February; 29 Suppl 1: S14-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11840156&dopt=Abstract

•

Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases. Author(s): Agarwal B, Naresh KN. Source: American Journal of Hematology. 2002 August; 70(4): 278-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12210808&dopt=Abstract

•

Bcl-2 gene rearrangements and apoptosis rates in patients with non-Hodgkin's lymphoma during chemotherapy. Author(s): Yazici H, Yalcinkaya L, Inanc S, Onat H, Saip P, Dalay N. Source: Clinical Biochemistry. 1999 February; 32(1): 45-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10074891&dopt=Abstract

•

BCL-6 in the pathogenesis of non-Hodgkin's lymphoma. Author(s): Ye BH. Source: Cancer Investigation. 2000; 18(4): 356-65. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10808372&dopt=Abstract

•

Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Author(s): Rummel MJ, Mitrou PS, Hoelzer D. Source: Seminars in Oncology. 2002 August; 29(4 Suppl 13): 27-32. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12170430&dopt=Abstract

•

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Author(s): Weidmann E, Kim SZ, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou PS. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 August; 13(8): 1285-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12181253&dopt=Abstract

Studies 19

•

Benzene and non-Hodgkin's lymphoma. Author(s): O'Connor SR, Farmer PB, Lauder I. Source: The Journal of Pathology. 1999 December; 189(4): 448-53. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10629542&dopt=Abstract

•

Beta-thalassemia intermedia and non-Hodgkin's lymphoma. Author(s): Chehal A, Loutfi R, Taher A. Source: Hemoglobin. 2002 August; 26(3): 219-25. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12403486&dopt=Abstract

•

Bilateral adrenal non-Hodgkin's lymphoma with adrenal insufficiency. Author(s): Ellis RD, Read D. Source: Postgraduate Medical Journal. 2000 August; 76(898): 508-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10908383&dopt=Abstract

•

Bilateral chylothorax due to retrosternal goiter in a patient with non-Hodgkin's lymphoma. Author(s): Simmgen M, Newlands ES, Southcott BM, Vigushin DM. Source: Medical Oncology (Northwood, London, England). 2001; 18(2): 153-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11778762&dopt=Abstract

•

Bilateral lacrimal sac fistulas in a patient with nasopharyngeal non-Hodgkin's lymphoma. Author(s): Kiratli H, Elgin U, Kiratli PO, Bekdik CF. Source: Journal of Pediatric Ophthalmology and Strabismus. 1998 May-June; 35(3): 1778. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9627882&dopt=Abstract

•

Bilateral upper and lower lid fatty herniation: an unusual presentation of nonHodgkin's lymphoma. Author(s): Bracaglia R, Fortunato R, Gentileschi S, La Rocca LM, Bruno I. Source: British Journal of Plastic Surgery. 2003 January; 56(1): 53-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12706154&dopt=Abstract

•

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Author(s): Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR. Source: Critical Reviews in Oncology/Hematology. 2001 July-August; 39(1-2): 181-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11418315&dopt=Abstract


•

Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Author(s): Scheidhauer K, Wolf I, Baumgartl HJ, Von Schilling C, Schmidt B, Reidel G, Peschel C, Schwaiger M. Source: European Journal of Nuclear Medicine and Molecular Imaging. 2002 October; 29(10): 1276-82. Epub 2002 July 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12271407&dopt=Abstract

•

Biology of non-Hodgkin's lymphoma. Author(s): Knowles DM. Source: Cancer Treat Res. 2001; 104: 149-200. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11191126&dopt=Abstract

•

Blood and marrow transplantation in relapsed or refractory non-Hodgkin's lymphoma. Author(s): Stiff PJ. Source: Oncology (Huntingt). 1998 October; 12(10 Suppl 8): 56-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9830634&dopt=Abstract

•

Blood levels of organochlorines before and after chemotherapy among nonHodgkin's lymphoma patients. Author(s): Baris D, Kwak LW, Rothman N, Wilson W, Manns A, Tarone RE, Hartge P. Source: Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2000 February; 9(2): 193-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10698481&dopt=Abstract

•

Blood transfusion and risk of non-Hodgkin's lymphoma. Author(s): Maguire-Boston EK, Suman V, Jacobsen SJ, Moore SB, Habermann TM, Cerhan JR, Folsom AR. Source: American Journal of Epidemiology. 1999 June 15; 149(12): 1113-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10369505&dopt=Abstract

•

Blood transfusions and non-Hodgkin's lymphoma. Author(s): Chow EJ, Holly EA. Source: Epidemiologic Reviews. 2002; 24(2): 269-79. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12762097&dopt=Abstract

Studies 21

•

Blood transfusions and risk of non-Hodgkin's lymphoma subtypes and chronic lymphocytic leukemia. Author(s): Cerhan JR, Wallace RB, Dick F, Kemp J, Parker AS, Zheng W, Sellers TA, Folsom AR. Source: Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2001 April; 10(4): 361-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11319177&dopt=Abstract

•

Blood transfusions and the risk of intermediate- or high-grade non-Hodgkin's lymphoma. Author(s): Nelson RA, Levine AM, Bernstein L. Source: Journal of the National Cancer Institute. 1998 November 18; 90(22): 1742-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9827530&dopt=Abstract

•

Blood transfusions as a risk factor for non-Hodgkin's lymphoma in the San Francisco Bay Area: a population-based study. Author(s): Chow EJ, Holly EA. Source: American Journal of Epidemiology. 2002 April 15; 155(8): 725-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943690&dopt=Abstract

•

BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Author(s): Briones J, Timmerman JM, Hilbert DM, Levy R. Source: Experimental Hematology. 2002 February; 30(2): 135-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11823048&dopt=Abstract

•

Bone marrow and peripheral blood changes in non-Hodgkin's lymphoma. Author(s): Lim EJ, Peh SC. Source: Singapore Med J. 2000 June; 41(6): 279-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11109344&dopt=Abstract

•

Bone marrow involvement and the prognosis of low grade non-Hodgkin's lymphoma. Author(s): Zemunik T, Vuckovic J, Marinkovic M, Forempoher G. Source: Croatian Medical Journal. 1998 December; 39(4): 419-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9841943&dopt=Abstract

•

Bone marrow necrosis in adult acute leukemia and non-Hodgkin's lymphoma. Author(s): Forrest DL, Mack BJ, Nevill TJ, Couban SH, Zayed E, Foyle A. Source: Leukemia & Lymphoma. 2000 August; 38(5-6): 627-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10953985&dopt=Abstract


•

Bone marrow staging of patients with non-Hodgkin's lymphoma: is flow cytometry a useful test? Author(s): Auer I, Luider J. Source: Cancer. 1999 January 1; 85(1): 240-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9921998&dopt=Abstract

•

Bowel perforation during chemotherapy for non-hodgkin's lymphoma. Author(s): Sakakura C, Hagiwara A, Nakanishi M, Yasuoka R, Shirasu M, Togawa T, Taniwaki M, Yamagishi H. Source: Hepatogastroenterology. 1999 November-December; 46(30): 3175-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10626181&dopt=Abstract

•

Breast cancer and splenic non-Hodgkin's lymphoma, a rare occurrence. Author(s): Engin H, Baltali E, Oyan B, Goksel H, Demirel B. Source: The Breast Journal. 2002 November-December; 8(6): 400-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12390369&dopt=Abstract

•

Breast metastasis of non-Hodgkin's lymphoma: evaluation with Ga-67 scintigraphy. Author(s): Hama Y, Kosuda S, Uematsu M, Kusano S. Source: Clinical Nuclear Medicine. 2000 July; 25(7): 549-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10885701&dopt=Abstract

•

Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Author(s): Kiss TL, Panzarella T, Messner HA, Meharchand J, Reddy V, Schimmer AD, Lipton JH. Source: Bone Marrow Transplantation. 2003 January; 31(2): 73-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12621486&dopt=Abstract

•

Cardiac involvement in non-Hodgkin's lymphoma. Author(s): Magagnoli M, Nozza A, Romano Lutman F, Santoro A. Source: British Journal of Haematology. 2002 December; 119(4): 887. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12472562&dopt=Abstract

•

Case report: extranodal non-Hodgkin's lymphoma of the parapharyngeal space. Author(s): Tulin Kayhan F, Ozkul N. Source: Auris, Nasus, Larynx. 1999 April; 26(2): 201-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10214901&dopt=Abstract

Studies 23

•

Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Author(s): Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 July; 13(7): 1099-107. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12176790&dopt=Abstract

•

Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Author(s): Bokstein F, Lossos A, Lossos IS, Siegal T. Source: Leukemia & Lymphoma. 2002 March; 43(3): 587-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12002763&dopt=Abstract

•

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma. Author(s): Chim CS, Kwong YL, Lie AK, Lee CK, Liang R. Source: Hematological Oncology. 1998 September; 16(3): 117-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10235070&dopt=Abstract

•

Challenging problems in advanced malignancy: Case 1. Chylopericardium during the treatment of non-Hodgkin's lymphoma. Author(s): Lee YH, Im SA, Nam SH, Lee SN, Kim Y, Seong CM, Han WS, Lee SW, Park SH, Lee SN. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 August 15; 21(16): 3168-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12915608&dopt=Abstract

•

Challenging problems in advanced malignancy: Case 4. Use of positron emission tomography to solve a diagnostic dilemma in a patient with non-Hodgkin's lymphoma. Author(s): Hennessy BT, Horgan A, Hogan M, Barry J, Reilly SO, Breathnach O. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 August 15; 21(16): 3173-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12915611&dopt=Abstract

•

Characteristics and survival of patients with non-Hodgkin's lymphoma with and without acquired immunodeficiency syndrome. Author(s): Diamond C, Taylor TH, Anton-Culver H. Source: Hematological Oncology. 2002 December; 20(4): 177-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12469327&dopt=Abstract


•

Characterization of Epstein-Barr virus genotype in AIDS-related non-Hodgkin's lymphoma. Author(s): Fassone L, Cingolani A, Martini M, Migliaretti G, Oreste PL, Capello D, Gloghini A, Vivenza D, Dolcetti R, Carbone A, Antinori A, Gaidano G, Larocca LM. Source: Aids Research and Human Retroviruses. 2002 January 1; 18(1): 19-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11804553&dopt=Abstract

•

Characterization of t(3;6)(q27;p21) breakpoints in B-cell non-Hodgkin's lymphoma and construction of the histone H4/BCL6 fusion gene, leading to altered expression of Bcl-6. Author(s): Kurata M, Maesako Y, Ueda C, Nishikori M, Akasaka T, Uchiyama T, Ohno H. Source: Cancer Research. 2002 November 1; 62(21): 6224-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12414651&dopt=Abstract

•

Characterization of T-cell non-Hodgkin's lymphoma and its association with EpsteinBarr virus in Pakistani patients. Author(s): Noorali S, Pervez S, Moatter T, Soomro IN, Kazmi SU, Nasir MI, Smith JL. Source: Leukemia & Lymphoma. 2003 May; 44(5): 807-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802918&dopt=Abstract

•

Chemotherapy combined with interferon-alpha in hepatitis B virus carriers with nonHodgkin's lymphoma. Author(s): Matano S, Kobayashi K, Ohta H, Minouchi K, Sanada T, Sugimoto T. Source: Acta Haematologica. 2002; 107(1): 46-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11818673&dopt=Abstract

•

Childhood exposure to simian virus 40-contaminated poliovirus vaccine and risk of AIDS-associated non-Hodgkin's lymphoma. Author(s): Engels EA, Rodman LH, Frisch M, Goedert JJ, Biggar RJ. Source: International Journal of Cancer. Journal International Du Cancer. 2003 August 20; 106(2): 283-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12800207&dopt=Abstract

•

Childhood leukaemia and non-Hodgkin's lymphoma in relation to proximity to railways. Author(s): Dickinson HO, Hammal DM, Dummer TJ, Parker L, Bithell JF. Source: British Journal of Cancer. 2003 March 10; 88(5): 695-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12618876&dopt=Abstract

Studies 25

•

Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study. Author(s): Van Oers MH, Hagenbeek A, Van Glabbeke M, Teodorovic I. Source: Annals of Hematology. 2002 October; 81(10): 553-7. Epub 2002 October 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12424535&dopt=Abstract

•

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. Author(s): Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 August 15; 21(16): 3041-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12915593&dopt=Abstract

•

Chylothorax in a case of Non-Hodgkin's lymphoma. Author(s): Naseer A, Saeed W. Source: J Coll Physicians Surg Pak. 2003 February; 13(2): 108-10. Erratum In: J Coll Physicians Surg Pak. 2003 July; 13(7): 422. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12685957&dopt=Abstract

•

Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1. Author(s): Moller MB, Skjodt K, Mortensen LS, Pedersen NT. Source: British Journal of Haematology. 1999 June; 105(3): 730-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10354138&dopt=Abstract

•

Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma. Author(s): Niitsu N, Honma Y, Iijima K, Takagi T, Higashihara M, Sawada U, OkabeKado J. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 January; 17(1): 196-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12529678&dopt=Abstract

•

Clinical trials referral resource. Current clinical trials in non-Hodgkin's lymphoma. Author(s): Cheson BD, West PJ. Source: Oncology (Huntingt). 2002 June; 16(6): 762-3, 766. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12088298&dopt=Abstract


•

c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma. Author(s): Aref S, Fouda M, El-Dosoky E, Menessy A, Mabed M, Saleeb M, Zalata K. Source: Hematology (Amsterdam, Netherlands). 2003 June; 8(3): 183-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12745652&dopt=Abstract

•

CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience. Author(s): Vose JM, Weisenburger DD, Lynch JC, Bierman PJ, Chan JC, Bast M, Aoun P, Bociek G, Greiner T, Armitage JO; Nebraska Lymphomas Study Group. Source: Leukemia & Lymphoma. 2002 April; 43(4): 799-804. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12153167&dopt=Abstract

•

CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Author(s): Buckstein R, Lim W, Franssen E, Imrie KL. Source: Leukemia & Lymphoma. 2003 June; 44(6): 955-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12854893&dopt=Abstract

•

Colovesical fistula an unusual complication of cytotoxic therapy in a case of nonHodgkin's lymphoma. Author(s): Ansari MS, Nabi G, Singh I, Hemal AK, Pandey G. Source: International Urology and Nephrology. 2001; 33(2): 373-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12092659&dopt=Abstract

•

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Author(s): Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J, Freedman AS. Source: British Journal of Haematology. 2002 June; 117(4): 828-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12060117&dopt=Abstract

•

Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. Author(s): Augustine SC, Norenberg JP, Colcher DM, Vose JM, Gobar LS, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero MA. Source: Journal of the American Pharmaceutical Association (Washington,D.C. : 1996). 2002 January-February; 42(1): 93-100. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11833524&dopt=Abstract

Studies 27

•

Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Author(s): Leonard JP, Siegel JA, Goldsmith SJ. Source: Cancer Investigation. 2003 April; 21(2): 241-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743990&dopt=Abstract

•

Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma. Author(s): Numbenjapon T, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W. Source: J Med Assoc Thai. 2002 November; 85(11): 1156-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12546311&dopt=Abstract

•

Comparison of interviewed and non-interviewed non-Hodgkin's lymphoma (NHL) patients in the San Francisco Bay Area. Author(s): Holly EA, Gautam M, Bracci PM. Source: Annals of Epidemiology. 2002 August; 12(6): 419-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12160601&dopt=Abstract

•

Complete remission of tumour with interleukin 2 therapy in a patient with nonHodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis. Author(s): Kiss TL, Spaner D, Daly AS, Hasegawa WS, Lipton JH, Messner HA, Chang H. Source: British Journal of Haematology. 2003 February; 120(3): 523-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12580972&dopt=Abstract

•

Composite germ cell tumor and B-cell non-Hodgkin's lymphoma arising in the sella turcica. Author(s): Valdez R, McKeever P, Finn WG, Gebarski S, Schnitzer B. Source: Human Pathology. 2002 October; 33(10): 1044-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12395379&dopt=Abstract

•

Constrictive pericarditis caused by infiltration of non-Hodgkin's lymphoma. Author(s): Noma T, Mizushige K, Kohno M. Source: Heart (British Cardiac Society). 2002 August; 88(2): 148. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12117839&dopt=Abstract


•

Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma. Author(s): Perez-Encinas M, Quintas A, Bendana A, Rabunal MJ, Bello JL. Source: Leukemia & Lymphoma. 1999 May; 33(5-6): 551-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10342582&dopt=Abstract

•

Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. Author(s): Aydin F, Yilmaz M, Ozdemir F, Kavgaci H, Yavuz MN, Yavuz AA. Source: American Journal of Clinical Oncology : the Official Publication of the American Radium Society. 2002 December; 25(6): 570-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12478000&dopt=Abstract

•

Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma. Author(s): van Agthoven M, Faber LM, Uyl-de Groot CA, Sonneveld P, Verdonck LF, Willemze R, Kluin-Nelemans JC, Lowenberg B, Huijgens PC. Source: European Journal of Haematology. 2002 October; 69(4): 213-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12431240&dopt=Abstract

•

Current and future uses of recombinant interferon alpha in the treatment of lowgrade non-Hodgkin's lymphoma. Author(s): Steis RG, Foon KA, Longo DL. Source: Cancer. 1987 February 1; 59(3 Suppl): 658-63. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10822466&dopt=Abstract

•

Current role and future perspectives for ifosfamide in the treatment of malignant non-Hodgkin's lymphoma--results from an expert meeting. Author(s): Sneller V, Armitage J. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003; 14 Suppl 1: I1-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12736223&dopt=Abstract

•

Current treatment of follicular non-Hodgkin's lymphoma. Author(s): Reiser M, Diehl V. Source: European Journal of Cancer (Oxford, England : 1990). 2002 June; 38(9): 1167-72. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044501&dopt=Abstract

Studies 29

•

Cutaneous granulomas associated with high-grade T-cell non-Hodgkin's lymphoma. Author(s): Farrell AM, Henry K, Woodrow D, Francis N, Newlands ES, Mitchell DN, Cream JJ. Source: The British Journal of Dermatology. 1999 January; 140(1): 145-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10215786&dopt=Abstract

•

CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Author(s): Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, Pruneri G, Martinelli G. Source: Cancer Research. 2002 June 1; 62(11): 3106-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12036921&dopt=Abstract

•

Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma. Author(s): Imrie KR, Linch DC, Czuczman MS. Source: Anti-Cancer Drugs. 2002 November; 13 Suppl 2: S19-24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12710587&dopt=Abstract

•

Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. Author(s): Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Source: Aids (London, England). 2001 March 30; 15(5): 629-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11317001&dopt=Abstract

•

Delayed diagnosis of primary non-Hodgkin's lymphoma of the sacrum. Author(s): Theodorou DJ, Theodorou SJ, Sartoris DJ, Haghighi P, Resnick D. Source: Clinical Imaging. 2000 May-June; 24(3): 169-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11150687&dopt=Abstract

•

Delineation of the frequently deleted region on chromosome arm 13q in B-cell nonHodgkin's lymphoma. Author(s): Wada M, Okamura T, Okada M, Teramura M, Masuda M, Motoji T, Mizoguchi H. Source: International Journal of Hematology. 2000 February; 71(2): 159-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10745626&dopt=Abstract

•

Delivery of full dose CHOP chemotherapy to elderly patients with aggressive nonHodgkin's lymphoma without G-CSF support. Author(s): Campbell C, Sawka C, Franssen E, Berinstein NL. Source: Leukemia & Lymphoma. 1999 September; 35(1-2): 119-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10512169&dopt=Abstract


•

Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells. Author(s): Aurlien E, Larsen RH, Kvalheim G, Bruland OS. Source: British Journal of Cancer. 2000 November; 83(10): 1375-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11044364&dopt=Abstract

•

Descriptive epidemiology of gastrointestinal non-Hodgkin's lymphoma in a population-based registry. Author(s): Gurney KA, Cartwright RA, Gilman EA. Source: British Journal of Cancer. 1999 April; 79(11-12): 1929-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10206316&dopt=Abstract

•

Detection of a non-Hodgkin's lymphoma by capromab pendetide scintigraphy (ProstaScint) in a patient with prostate carcinoma. Author(s): Zanzi I, Stark R. Source: Urology. 2002 September; 60(3): 514. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12350503&dopt=Abstract

•

Detection of abundantly transcribed genes and gene translocation in human immunodeficiency virus-associated non-Hodgkin's lymphoma. Author(s): Tarantul V, Nikolaev A, Hannig H, Kalmyrzaev B, Muchoyan I, Maximov V, Nenasheva V, Dubovaya V, Hunsmann G, Bodemer W. Source: Neoplasia (New York, N.Y.). 2001 March-April; 3(2): 132-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11420749&dopt=Abstract

•

Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. Author(s): Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA, Matthews J, Foot NJ, Young BD, Lister TA, Rohatiner AZ. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001 May 1; 19(9): 2472-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11331326&dopt=Abstract

•

Detection of concurrent/recurrent non-Hodgkin's lymphoma in effusions by PCR. Author(s): Murphy M, Signoretti S, Nasser I, Sherburne B, Loda M. Source: Human Pathology. 1999 November; 30(11): 1361-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10571518&dopt=Abstract

•

Detection of non-Hodgkin's lymphoma liver disease in cirrhotic patients. Author(s): Picardi M, De Renzo A, Falzarano G, Vecchione R, D'Armiento M, Rotoli B. Source: Haematologica. 1999 March; 84(3): 278-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10189397&dopt=Abstract

Studies 31

•

Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. Author(s): Elis A, Blickstein D, Klein O, Eliav-Ronen R, Manor Y, Lishner M. Source: American Journal of Hematology. 2002 January; 69(1): 41-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11835330&dopt=Abstract

•

Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization. Author(s): Sanchez-Izquierdo D, Siebert R, Harder L, Marugan I, Gozzetti A, Price HP, Gesk S, Hernandez-Rivas JM, Benet I, Sole F, Sonoki T, Le Beau MM, Schlegelberger B, Dyer MJ, Garcia-Conde J, Martinez-Climent JA. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2001 September; 15(9): 1475-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11516111&dopt=Abstract

•

Development of anti-VWF antibody in a patient with severe haemophilia A following the development of high-grade non-Hodgkin's lymphoma. Author(s): Ghosh K, Shetty S, Jijina F, Mohanty D. Source: Clinical and Laboratory Haematology. 2002 June; 24(3): 191-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12067287&dopt=Abstract

•

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Author(s): Multani P. Source: International Journal of Hematology. 2002 December; 76(5): 401-10. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12512834&dopt=Abstract

•

Dexa-BEAM is not effective in patients with relapsed or resistant aggressive highgrade non-Hodgkin's lymphoma. Author(s): Reiser M, Josting A, Dias Wickramanayake P, Draube A, Scheid C, Tesch H, Wolf J, Diehl V, Engert A. Source: Leukemia & Lymphoma. 1999 April; 33(3-4): 305-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10221510&dopt=Abstract

•

Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Author(s): Machover D, Delmas-Marsalet B, Misra SC, Gumus Y, Goldschmidt E, Schilf A, Frenoy N, Emile JF, Debuire B, Guettier C, Farrokhi P, Boulefdaoui B, Norol F, Parquet N, Ulusakarya A, Jasmin C. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2001 October; 12(10): 1439-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11762817&dopt=Abstract


•

DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Author(s): Coleman M, Leonard J, Shuster MW, Kaufman TP. Source: European Journal of Haematology. Supplementum. 2001 July; (64): 41-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11486401&dopt=Abstract

•

Dichotomy between Tc-99m MDP bone scan and fluorine-18 fluorodeoxyglucose coincidence detection positron emission tomography in patients with non-Hodgkin's lymphoma. Author(s): Lee J, Park CH, Kim HC, Kim HS. Source: Clinical Nuclear Medicine. 2000 July; 25(7): 532-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10885695&dopt=Abstract

•

Dietary fat and protein in relation to risk of non-Hodgkin's lymphoma among women. Author(s): Zhang S, Hunter DJ, Rosner BA, Colditz GA, Fuchs CS, Speizer FE, Willett WC. Source: Journal of the National Cancer Institute. 1999 October 20; 91(20): 1751-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10528026&dopt=Abstract

•

Differential gene expression in B-cell non-Hodgkin's lymphoma of SIV-infected monkey. Author(s): Tarantul VZ, Nikolaev AI, Martynenko A, Hannig H, Hunsmann G, Bodemer W. Source: Aids Research and Human Retroviruses. 2000 January 20; 16(2): 173-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10659056&dopt=Abstract

•

Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. Author(s): Gazitt Y, Shaughnessy P, Liu Q. Source: Journal of Hematotherapy & Stem Cell Research. 2001 February; 10(1): 167-76. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11276370&dopt=Abstract

•

Differentiation between non-Hodgkin's lymphoma recurrence and second primary lymphoma by VDJ rearrangement analysis. Author(s): Libra M, De Re V, Gasparotto D, Gloghini A, Marzotto A, Milan I, Tirelli U, Stivala F, Carbone A, Boiocchi M. Source: British Journal of Haematology. 2002 September; 118(3): 809-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12181049&dopt=Abstract

Studies 33

•

Difficulties in differentiating endoscopically primary from secondary gastric nonHodgkin's lymphoma. Author(s): Tursi A. Source: Gastrointestinal Endoscopy. 2000 July; 52(1): 146-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10882989&dopt=Abstract

•

Diffuse large B-cell non-Hodgkin's lymphoma in a patient with autoimmune lymphoproliferative syndrome. Author(s): Boulanger E, Rieux-Laucat F, Picard C, Legall M, Sigaux F, Clauvel JP, Oksenhendler E, Le Deist F, Meignin V. Source: British Journal of Haematology. 2001 May; 113(2): 432-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11380411&dopt=Abstract

•

Diffuse large B-cell non-Hodgkin's lymphoma presenting as a vaginal mass in a patient with a history of intestinal mucosa-associated lymphoid tissue (MALT) lymphoma. Author(s): Hosing C, Freedman RS, McLaughlin P, Malpica A, Fornage BD, Kudelka AP. Source: American Journal of Clinical Oncology : the Official Publication of the American Radium Society. 2001 April; 24(2): 204-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11319299&dopt=Abstract

•

Diffuse large B-cell non-Hodgkin's lymphoma presenting as Sister Joseph's nodule. Author(s): Tam C, Turner H, Hicks RJ, Seymour JF. Source: Leukemia & Lymphoma. 2002 October; 43(10): 2055-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12481909&dopt=Abstract

•

Diplopia as an initial manifestation of disseminated non-hodgkin's lymphoma. Author(s): Claeys A, Trullemans F, Maes J, Hennekes R, Salu P. Source: Bull Soc Belge Ophtalmol. 2002; (286): 35-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12564315&dopt=Abstract

•

Direct Epstein-Barr virus (EBV) typing on peripheral blood mononuclear cells: no association between EBV type 2 infection or superinfection and the development of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Author(s): van Baarle D, Hovenkamp E, Kersten MJ, Klein MR, Miedema F, van Oers MH. Source: Blood. 1999 June 1; 93(11): 3949-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10339504&dopt=Abstract


•

Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Author(s): Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT. Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 1999 May; 5(5): 1085-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10353742&dopt=Abstract

•

Disseminated cutaneous Mycobacterium marinum infection in a patient with nonHodgkin's lymphoma. Author(s): Enzensberger R, Hunfeld KP, Elshorst-Schmidt T, Boer A, Brade V. Source: Infection. 2002 December; 30(6): 393-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12478331&dopt=Abstract

•

Distribution of various subtypes of non-Hodgkin's lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications. Author(s): Naresh KN, Srinivas V, Soman CS. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2000; 11 Suppl 1: 63-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10707782&dopt=Abstract

•

DNA polymerase chain reaction using fine needle aspiration biopsy smears to evaluate non-Hodgkin's lymphoma. Author(s): Grosso LE, Collins BT. Source: Acta Cytol. 1999 September-October; 43(5): 837-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10518139&dopt=Abstract

•

Does asbestos exposure cause non-Hodgkin's lymphoma or related hematolymphoid cancers? A review of the epidemiologic literature. Author(s): Weisenburger DD, Chiu BC. Source: Clin Lymphoma. 2002 June; 3(1): 36-40. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12141953&dopt=Abstract

•

Dose-escalation of CHOP in non-Hodgkin's lymphoma. Author(s): Santoro A, Balzarotti M, Tondini C, Zanini M, Giardini R, Latteri F, Rampinelli I, Bufalino R. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1999 May; 10(5): 519-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10416000&dopt=Abstract

Studies 35

•

Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Author(s): Itoh K, Ohtsu T, Wakita H, Igarashi T, Ishizawa K, Onozawa Y, Fujii H, Minami H, Sasaki Y. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2000 October; 11(10): 1241-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11106111&dopt=Abstract

•

Double-phase Tc-99m MIBI scintigraphy as a therapeutic predictor in patients with non-Hodgkin's lymphoma. Author(s): Song HC, Lee JJ, Bom HS, Chung IJ, Kim HJ, Park YK, Kim EE. Source: Clinical Nuclear Medicine. 2003 June; 28(6): 457-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12911092&dopt=Abstract

•

Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma. Author(s): Mulder AH, Raemaekers JM, Boerman RH, Mattijssen V. Source: Annals of Hematology. 1999 February; 78(2): 105-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10089030&dopt=Abstract

•

Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Author(s): Vieira Pinheiro JP, Lanversa C, Wurthwein G, Beier R, Casimiro da Palma J, von Stackelberg A, Boos J. Source: Leukemia & Lymphoma. 2002 October; 43(10): 1911-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12481884&dopt=Abstract

•

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. Author(s): Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 April 1; 21(7): 1255-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12663712&dopt=Abstract

•

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Author(s): Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, Sabbah A, Woronoff-Lemsi MC, Cahn JY. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 February; 14(2): 277-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12562656&dopt=Abstract


•

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Author(s): Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2002 September; 13(9): 1356-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12196360&dopt=Abstract

•

E-cadherin expression in lymph nodes of three patients with non-Hodgkin's lymphoma. Author(s): Takubo T, Kanashima H, Terada Y, Shibata H, Aoyama Y, Nakamae H, Yamamura R, Shima E, Makita K, Tanaka K, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N, Ohshima K. Source: Haematologia. 2002; 32(1): 67-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12243557&dopt=Abstract

•

Echocardiographic assessment of right atrial thrombus related to the implanted port device in patient receiving chemotherapy for non-Hodgkin's lymphoma. Author(s): Ozimek W, Wroblewska-Kaluzewska M, Gadomski A, Sopylo B, RokickaMilewska R, Jaranowska D, Ebinger K, Malec Z, Brzewski M. Source: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2000 September-October; 6(5): 1013-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11208448&dopt=Abstract

•

Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. Author(s): Limat S, Woronoff-Lemsi MC, Milpied N, Chartrin I, Ifrah N, Deconinck E, Gressin R, Colombat P, Cahn JY, Arveux P; Groupe Ouest Est d'etude des Leucemies et Autres Maladies du Sang (GOELAMS). Source: European Journal of Cancer (Oxford, England : 1990). 2000 December; 36(18): 2360-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11094310&dopt=Abstract

•

Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. Author(s): Webb IJ, Friedberg W, Gribben JG, Fisher DC, Spitzer T, Neuberg D, Jallow H, Kim H, Houde H, Monroy R, Schmittling R, Freedman AS. Source: Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2002; 8(8): 429-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12234168&dopt=Abstract

Studies 37

•

Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma. Author(s): Enschede SH, Shahidi H, Venugopal P, Riley MB, Huang R, Jajeh A, Preisler HD, Gregory SA. Source: Leukemia & Lymphoma. 2001 January; 40(3-4): 325-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426554&dopt=Abstract

•

Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Author(s): Kaya H, Keung YK, Case D, Cruz JM, Perry JJ, Radford JE, Hurd DD. Source: Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2002; 8(10): 544-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12434949&dopt=Abstract

•

Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Author(s): Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH, Appelbaum FR, Press OW. Source: Bone Marrow Transplantation. 2001 March; 27(6): 593-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11319588&dopt=Abstract

•

Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. Author(s): Yoong Y, Kurtin PJ, Allmer C, Geyer S, Habermann TM, Nagorney DM, Witzig TE. Source: Leukemia & Lymphoma. 2001 November-December; 42(6): 1235-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11911404&dopt=Abstract

•

Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma. Author(s): Zinzani PL, Tani M, Stefoni V, Albertini P, Bendandi M, Gherlinzoni F, Alinari L, Vigna E, Tura S. Source: Haematologica. 2001 March; 86(3): 287-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11255276&dopt=Abstract

•

Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma. Author(s): Sasaki K, Niitsu N. Source: European Journal of Haematology. 2000 September; 65(3): 195-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11007056&dopt=Abstract


•

Enormous bilateral adrenal uptake of F-18 FDG caused by non-Hodgkin's lymphoma. Author(s): Brink I, Schneider B, Hoegerle S. Source: Clinical Nuclear Medicine. 2002 October; 27(10): 739-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352123&dopt=Abstract

•

Environmental risk factors for non-Hodgkin's lymphoma: a population-based casecontrol study in Languedoc-Roussillon, France. Author(s): Fabbro-Peray P, Daures JP, Rossi JF. Source: Cancer Causes & Control : Ccc. 2001 April; 12(3): 201-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11405325&dopt=Abstract

•

Eosinophilic pneumonia after administration of fludarabine for the treatment of nonHodgkin's lymphoma. Author(s): Trojan A, Meier R, Licht A, Taverna C. Source: Annals of Hematology. 2002 September; 81(9): 535-7. Epub 2002 August 01. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12373357&dopt=Abstract

•

Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Author(s): Anderson JR, Armitage JO, Weisenburger DD. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 1998 July; 9(7): 717-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9739436&dopt=Abstract

•

Epidural B cell non-Hodgkin's lymphoma associated with chronic subdural hematoma. Author(s): Alimehmeti R, Locatelli M. Source: Surgical Neurology. 2002 March; 57(3): 179-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12009545&dopt=Abstract

•

Epithelioid granulomas as main clinical manifestation at the outset of non-Hodgkin's lymphoma: report of two cases. Author(s): Lerza R, Schenone E, Barsotti BP, Botta M, Arboscello E, Truini M, Bogliolo G, Pannacciulli I. Source: Oncology Research. 2002; 13(1): 55-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12201675&dopt=Abstract

•

Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study. Author(s): Leong IT, Fernandes BJ, Mock D. Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 2001 August; 92(2): 184-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11505266&dopt=Abstract

Studies 39

•

Epstein-Barr virus-associated anaplastic large cell variant of diffuse large B-cell-type non-Hodgkin's lymphoma with concurrent p53 protein expression. Author(s): Hirose Y, Masaki Y, Shimoyama K, Fukushima T, Kawabata H, Ogawa N, Wano Y, Sugai S. Source: International Journal of Hematology. 2003 June; 77(5): 499-502. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12841389&dopt=Abstract

•

Epstein-Barr virus-associated B-cell type non-Hodgkin's lymphoma with concurrent p53 protein expression in a rheumatoid arthritis patient treated with methotrexate. Author(s): Hirose Y, Masaki Y, Okada J, Kim CG, Kawabata H, Ogawa N, Wano Y, Sugai S. Source: International Journal of Hematology. 2002 May; 75(4): 412-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12041674&dopt=Abstract

•

Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis. Author(s): Mitarnun W, Pradutkanchana J, Takao S, Saechan V, Suwiwat S, Ishida T. Source: J Med Assoc Thai. 2002 May; 85(5): 552-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12188384&dopt=Abstract

•

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma. Author(s): Choi CW, Paek CW, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS. Source: Journal of Korean Medical Science. 2002 October; 17(5): 621-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12378012&dopt=Abstract

•

Establishing a radioimmunotherapy outpatient care clinic for Non-Hodgkin's lymphoma. Author(s): Hendrix C, de Leon C. Source: Semin Oncol Nurs. 2002 February; 18(1 Suppl 1): 22-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11878048&dopt=Abstract

•

Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. Author(s): Doorduijn JK, Spruit P, van Der Holt B, van't Veer M, Budel L, Lowenberg B, Sonneveld P. Source: Haematologica. 2000 August; 85(8): 814-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10942927&dopt=Abstract


•

Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Author(s): Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, AlKatib AM. Source: Anti-Cancer Drugs. 2001 January; 12(1): 57-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11272287&dopt=Abstract

•

Ex vivo expansion of CD34-positive peripheral blood progenitor cells from patients with non-Hodgkin's lymphoma: no evidence of concomitant expansion of contaminating bcl2/JH-positive lymphoma cells. Author(s): Yao M, Fouillard L, Lemoine FM, Bouchet S, Firat H, Andreu G, Gorin NC, Douay L, Lopez M. Source: Bone Marrow Transplantation. 2000 September; 26(5): 497-503. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11019838&dopt=Abstract

•

Excellent tolerance of rituximab when given after mitoxantrone/cyclophosphamide: an effective and safe combination for indolent non-Hodgkin's lymphoma. Author(s): Emmanouilides C, Rosen P, Telatar M, Malone R, Bosserman L, Menco H, Patel R, Barstis J, Grody WW. Source: Clin Lymphoma. 2000 September; 1(2): 146-51; Discussion 152-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11707827&dopt=Abstract

•

Experience with 9-cis retinoic acid in patients with relapsed and refractory nonHodgkin's lymphoma. Author(s): Younes A, Cristofanilli M, McLaughlin P, Hagemeister FB, Weber D, Mesina O, Cabanillas F. Source: Leukemia & Lymphoma. 2000 December; 40(1-2): 79-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426631&dopt=Abstract

•

Exposure to pesticides as risk factor for non-Hodgkin's lymphoma and hairy cell leukemia: pooled analysis of two Swedish case-control studies. Author(s): Hardell L, Eriksson M, Nordstrom M. Source: Leukemia & Lymphoma. 2002 May; 43(5): 1043-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12148884&dopt=Abstract

•

Expression and function of CD28 on Epstein-Barr virus-positive B cell lines and AIDS-associated non-Hodgkin's lymphoma cell lines. Author(s): Widney D, Boscardin WJ, Kasravi A, Martinez-Maza O. Source: Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine. 2003 March-April; 24(2): 82-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12853703&dopt=Abstract

Studies 41

•

Expression of adhesion molecules on CD34(+) cells in peripheral blood of nonhodgkin's lymphoma patients mobilized with different growth factors. Author(s): Gazitt Y, Shaughnessy P, Liu Q. Source: Stem Cells (Dayton, Ohio). 2001; 19(2): 134-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11239168&dopt=Abstract

•

Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Author(s): Stewart M, Talks K, Leek R, Turley H, Pezzella F, Harris A, Gatter K. Source: Histopathology. 2002 March; 40(3): 253-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11895491&dopt=Abstract

•

Expression of basic fibroblast growth factor is associated with poor outcome in nonHodgkin's lymphoma. Author(s): Pazgal I, Zimra Y, Tzabar C, Okon E, Rabizadeh E, Shaklai M, Bairey O. Source: British Journal of Cancer. 2002 June 5; 86(11): 1770-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12087465&dopt=Abstract

•

Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma and its prognostic implications. Author(s): Jin YH, Park CK. Source: Journal of Korean Medical Science. 2002 June; 17(3): 322-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12068134&dopt=Abstract

•

Expression of transmembrane 4 superfamily member, CD9, is related to improved progression-free survival in patients with diffuse non-Hodgkin's lymphoma. Author(s): Yau JC, Dabbagh LK, Formenti KS, Coupland RW, Burns BF, Shaw AR. Source: Oncol Rep. 1998 November-December; 5(6): 1507-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9769396&dopt=Abstract

•

Extensive jugular and upper limb thrombosis in a patient with factor V Leiden mutation and non-Hodgkin's lymphoma. Author(s): Cakir M, Gurkan OU, Savas I, Numanoglu N, Ataman S, Ekinci C, Akar N. Source: Aust N Z J Med. 2000 December; 30(6): 735-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11198590&dopt=Abstract

•

External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin's lymphoma. Author(s): Briggs JH, Algan O, Miller TP, Oleson JR. Source: American Journal of Clinical Oncology : the Official Publication of the American Radium Society. 2002 February; 25(1): 34-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11823692&dopt=Abstract


•

Extranodal non-Hodgkin's lymphoma of the maxillofacial region: analysis of 88 consecutive cases. Author(s): Maxymiw WG, Goldstein M, Wood RE. Source: Sadj. 2001 November; 56(11): 524-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11885430&dopt=Abstract

•

F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. Author(s): Shih WJ, Ghesani N, Hongming Z, Alavi A, Schusper S, Mozley D. Source: Clinical Nuclear Medicine. 2002 February; 27(2): 142-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11786752&dopt=Abstract

•

F-18 FDG positron emission tomography in primary breast non-Hodgkin's lymphoma. Author(s): Bakheet SM, Bakheet R, Ezzat A, Tulbah A, Durakovic A, Hussain S. Source: Clinical Nuclear Medicine. 2001 April; 26(4): 299-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11290887&dopt=Abstract

•

Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Author(s): DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR. Source: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 1999 August; 40(8): 1317-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10450684&dopt=Abstract

•

Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. Author(s): Dumontet C, Mounier N, Munck JN, Bosly A, Morschauser F, Simon D, Marit G, Casasnovas O, Reman O, Molina T, Reyes F, Coiffier B. Source: British Journal of Haematology. 2002 July; 118(1): 210-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12100150&dopt=Abstract

•

Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Author(s): Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM, Leonhardt M, Bradburn M, Okukenu E, Salam A, Matthews J, Cavenagh JD, Gupta RK, Lister TA. Source: The Hematology Journal : the Official Journal of the European Haematology Association / Eha. 2000; 1(6): 367-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11920216&dopt=Abstract

Studies 43

•

False-positive F-18 FDG gamma camera positron emission tomographic imaging resulting from inflammation of an anterior mediastinal mass in a patient with nonHodgkin's lymphoma. Author(s): Yoon SN, Park CH, Kim MK, Hwang KH, Kim S. Source: Clinical Nuclear Medicine. 2001 May; 26(5): 461-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11317035&dopt=Abstract

•

False-positive splenic imaging secondary to cavernous transformation of the portal venous system in non-Hodgkin's lymphoma. Author(s): Ignatow MJ, Mendelson DS. Source: Clinical Nuclear Medicine. 2003 February; 28(2): 124-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12544130&dopt=Abstract

•

Fas ligand expression in nodal non-Hodgkin's lymphoma. Author(s): Mullauer L, Mosberger I, Chott A. Source: Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. 1998 April; 11(4): 369-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9578088&dopt=Abstract

•

Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. Author(s): Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW, Johnston LF, Long GD, Strober S, Wong RM, Feiner RH, Kobler S, Negrin RS. Source: Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2000; 6(5): 506-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11063379&dopt=Abstract

•

Feasibility and efficacy of high-dose etoposide followed by low-dose G-CSF as a mobilization regimen in patients with non-Hodgkin's lymphoma. Author(s): Ashihara E, Shimazaki C, Okano A, Hatsuse M, Inaba T, Nakagawa M. Source: Haematologica. 2000 October; 85(10): 1112-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11025616&dopt=Abstract

•

Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Author(s): Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA, Colcher D. Source: Clin Lymphoma. 2001 December; 2(3): 164-72. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11779293&dopt=Abstract


•

Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients

Non-Hodgkin's Lymphoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Lymphoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Burkitt's Lymphoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

B-Cell Lymphoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Influenza A - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Hepatitis A Vaccine: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Foot and Mouth Disease - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Anagrelide: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Peanut Allergy: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Cauda Equina Syndrome - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Magnesium Citrate: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Lipomas - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Barbiturates - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Cephalexin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Body Dysmorphic Disorder: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Lymphedema - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Dermabrasion: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Septra: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Vaginitis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Feet - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Glioblastoma Multiforme - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Female Infertility - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Living Will - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Hip Pain: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Benzene - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Marburg Virus: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Erythema Multiforme - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Non-Hodgkin's Lymphoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Lymphoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Burkitt's Lymphoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

B-Cell Lymphoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Influenza A - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Hepatitis A Vaccine: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Foot and Mouth Disease - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Anagrelide: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Peanut Allergy: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Cauda Equina Syndrome - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Magnesium Citrate: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Lipomas - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Barbiturates - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Cephalexin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Body Dysmorphic Disorder: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Lymphedema - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Dermabrasion: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Septra: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Vaginitis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Feet - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Glioblastoma Multiforme - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Female Infertility - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Living Will - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Hip Pain: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Benzene - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Marburg Virus: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References

Erythema Multiforme - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Recommend Documents